IBRXHIGH SIGNALFINANCIAL10-K

IBRX achieved a dramatic 668% revenue surge to $113.3M driven by massive accounts receivable growth, while simultaneously reducing operating losses by 26% and cutting interest expense in half.

This represents a fundamental business transformation, with revenue exploding from $14.7M to $113.3M, suggesting either a major commercial breakthrough or significant new business activity. The 1,704% spike in accounts receivable to $42.6M indicates this revenue growth may be concentrated with specific customers or involves extended payment terms, requiring careful monitoring of collection risk.

Comparing 2026-02-23 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

IBRX delivered extraordinary financial improvements across multiple dimensions - revenue exploded 668% to $113.3M while operating losses narrowed 26% to -$256M and interest expense was slashed 47% to $60.9M. The company strengthened its balance sheet with total assets growing 31% to $501.9M and current assets up 71% to $314.9M, though cash declined 38% to $88.3M. The massive 1,704% surge in accounts receivable to $42.6M suggests the revenue growth may involve specific large customers or extended payment arrangements that warrant close attention.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
+1703.9%
$2.4M$42.6M

Receivables surged 1703.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Revenue
P&L
+668.3%
$14.7M$113.3M

Strong top-line growth of 668.3% — accelerating demand or successful expansion into new markets.

Inventory
Balance Sheet
-89%
$8.3M$910K

Inventory drawn down 89% — strong sell-through or deliberate destocking; watch for supply constraints.

Current Assets
Balance Sheet
+70.6%
$184.6M$314.9M

Current assets grew 70.6% — improving short-term liquidity or inventory/receivables build.

Interest Expense
P&L
-46.9%
$114.7M$60.9M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Capital Expenditure
Cash Flow
-44.2%
$6.9M$3.8M

Capex reduced 44.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-38.4%
$143.4M$88.3M

Cash declined 38.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Assets
Balance Sheet
+31.1%
$382.9M$501.9M

Asset base grew 31.1% — expansion through organic growth, acquisitions, or capital deployment.

SG&A Expense
P&L
+30.2%
$129.6M$168.8M

SG&A up 30.2% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Operating Income
P&L
+25.6%
-$344.2M-$256.0M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-02-23
PRIOR — 2025-03-03
ADDED
2015 Equity Incentive Plan 2015 Share Repurchase Program Board of Directors-approved share repurchase program 2025 Plan ImmunityBio, Inc.
2025 Equity Incentive Plan 3M IPC 3M Innovative Properties Company 3PL Agent logistics agent 401(k) Plan 401(k) retirement and savings plan AAHI Access to Advanced Health Institute ACA Affordable Care Act ADCC antibody-dependent cellular cytotoxicity AI artificial intelligence AKS Anti-Kickback Statute ALC absolute lymphocyte count Altor Altor BioScience, LLC America Invents Act Leahy-Smith America Invents Act Amyris Amyris, Inc.
Department of Commerce, Bureau of Industry and Security BLA Biologics License Application BPCIA Biologics Price Competition and Innovation Act of 2009 Brink Brink Biologics, Inc.
Cambridge Cambridge Equities, LP Cancer BioShield platform our first-in-class immunotherapy strategy designed to restore immune competence by reversing lymphopenia the loss of functional immune cells caused by cancer itself and by conventional treatments such as chemotherapy, radiation and immunotherapy.
CAP community-acquired pneumonia CAR chimeric antigen receptor CCPA California Consumer Privacy Act of 2018 CEO chief executive officer CFO chief financial officer cGMP current Good Manufacturing Practice China when used in connection with the RIPA, People s Republic of China, Hong Kong and any territories controlled by the People s Republic of China CHMP Committee for Medicinal Products for Human Use CI confidence interval CIO chief information officer CIS carcinoma in situ Clinic Immuno-Oncology Clinic, Inc.
+7 more — sign up free →
REMOVED
2015 Equity Incentive Plan 2015 Share Repurchase Program Board of Directors-approved share repurchase program 3M IPC 3M Innovative Properties Company 3PL Agent logistics agent 401(k) Plan 401(k) retirement and savings plan AAHI Access to Advanced Health Institute ACA Affordable Care Act ADCC antibody-dependent cellular cytotoxicity ALC absolute lymphocyte count Altor Altor BioScience, LLC America Invents Act Leahy-Smith America Invents Act Amyris Amyris, Inc.
ANC absolute neutrophil count aNK activated NK cells ANKTIVA Proprietary name for N-803 (formerly ALT-803), our novel IL-15 receptor superagonist complex (nogapendekin alfa inbakicept-pmln) currently approved for use in the United States with BCG for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, and currently in clinical development for other indications.
Annual Report Annual Report on Form 10-K for the year ended December 31, 2024 Approved product ANKTIVA ART anti-retroviral therapy ASC Accounting Standards Codification ASCO American Society of Clinical Oncology ASU Accounting Standards Update Athenex Athenex, Inc.
BLA Biologics License Application bNAbs broadly-neutralizing antibodies BPCIA Biologics Price Competition and Innovation Act of 2009 Brink Brink Biologics, Inc.
Cambridge Cambridge Equities, LP CAR chimeric antigen receptor CCPA California Consumer Privacy Act of 2018 CEO chief executive officer i Term Definition CFO chief financial officer cGMP current Good Manufacturing Practice China when used in connection with the RIPA, People s Republic of China, Hong Kong and any territories controlled by the People s Republic of China CI confidence interval CIO chief information officer CIS carcinoma in situ Clinic Immuno-Oncology Clinic, Inc.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →